Did You Know?

Editor’s Picks

Latest News

Mission Therapeutics strikes deal worth up to $292 million for Dimerix Ltd to develop Acute Kidney Injury asset MTX652, sharpens focus on its CNS pipeline

Mission Therapeutics has divested MTX652, a Phase 2-ready selective USP30 inhibitor for Acute Kidney Injury (AKI), to ASX-listed renal specialist...

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in...

UPDATE – Glucotrack and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform

Transaction positions the combined company to execute a capital-efficient, repeatable strategy leveraging public market access and Lōkahi Therapeutics ai²-driven asset...

error: Content is protected !!